CBCT for Cholesteatoma: How Cone Beam Imaging Supports Middle Ear Assessment and Surgical Planning

CBCT cholesteatoma imaging gives ENT surgeons a high-resolution, low-dose surgical roadmap before they enter the middle ear. In particular, it maps the bony erosion that shapes surgical approach and patient consent. For any otologist or ENT referrer weighing up imaging options ahead of cholesteatoma surgery, this guide explains when cone beam CT adds clinical value, what it reveals that conventional radiography cannot, and how to refer for a same-day temporal bone CBCT at 3Beam.

Quick Answer: Why Use CBCT Cholesteatoma Imaging Before Surgery?

Cholesteatoma erodes bone. Therefore, the surgeon needs to know precisely which structures remain intact and which have been compromised before the first incision. CBCT cholesteatoma imaging delivers sub-millimetre bony resolution of the temporal bone at a fraction of the radiation dose of conventional multislice CT. In particular, it maps ossicular chain erosion, scutum integrity, tegmen thinning, and the course of the facial nerve canal. This information directly shapes the choice between canal wall up and canal wall down tympanomastoidectomy.

What Is Cholesteatoma and Why Does Imaging Matter?

Cholesteatoma is a destructive, non-neoplastic mass of keratinising squamous epithelium within the middle ear or mastoid. Importantly, it expands progressively, eroding the ossicular chain, tegmen tympani, lateral semicircular canal, and facial nerve canal. As a result, untreated cholesteatoma can cause conductive hearing loss, facial nerve palsy, labyrinthine fistula, meningitis, and intracranial abscess.

Otoscopy and clinical examination identify the disease. However, they cannot reliably determine the full extent of bony erosion or the integrity of critical deep structures. For this reason, preoperative cross-sectional imaging is considered essential. The ESR Essentials consensus paper (European Radiology, 2025) confirms that CT remains the first-line preoperative imaging modality for cholesteatoma because it provides both a surgical roadmap and detection of erosive complications.

How CBCT Cholesteatoma Imaging Compares to Conventional CT

Conventional high-resolution multislice CT (HRCT) has long been the standard for temporal bone imaging. It offers excellent bony detail and fast acquisition. However, CBCT provides several specific advantages that make it increasingly relevant for cholesteatoma assessment in the outpatient setting.

Spatial resolution. Modern CBCT scanners achieve isotropic voxel sizes of 0.075 to 0.2 mm. In comparison, standard HRCT typically reconstructs at 0.5 to 0.625 mm slice thickness. As a result, CBCT depicts fine bony landmarks, including the stapes superstructure, the tympanic segment of the facial nerve canal, and the scutum, with notably greater clarity.

Radiation dose. Similarly, CBCT delivers a substantially lower effective dose than HRCT for temporal bone protocols. Published comparisons report effective doses of 0.01 to 0.10 mSv for CBCT, whereas HRCT temporal bone protocols typically range from 0.2 to 1.0 mSv. Consequently, for patients requiring serial imaging or bilateral assessment, this dose reduction is clinically meaningful.

Accessibility. Moreover, CBCT scanners are more widely available in outpatient and community settings than hospital-based multislice CT. At 3Beam’s temporal bone imaging service, for example, same-day appointments are available with consultant radiologist reporting included. This means the referring surgeon receives a formal clinical interpretation alongside the images.

Limitations to note. CBCT does not provide soft tissue contrast. Therefore, it cannot reliably differentiate cholesteatoma from middle ear effusion or granulation tissue. Additionally, CBCT acquisition times are longer than HRCT, which makes it more susceptible to motion artefacts. For soft tissue characterisation or postoperative recurrence surveillance, MRI with non-echoplanar diffusion-weighted imaging (non-EPI DWI) remains the appropriate modality.

What CBCT Cholesteatoma Scans Reveal for Surgical Planning

A well-performed temporal bone CBCT provides the surgeon with a detailed bony inventory of the middle ear and mastoid. Specifically, the scan addresses several critical surgical questions.

Ossicular chain status. First, CBCT identifies erosion of the long process of the incus, the incudostapedial joint, and the stapes superstructure. Notably, the long and lenticular processes of the incus are the structures most commonly eroded by cholesteatoma. Furthermore, knowing whether the stapes footplate is intact influences the feasibility of ossicular chain reconstruction.

Scutum and Prussak space. Second, pars flaccida cholesteatoma typically originates in Prussak space and erodes the scutum laterally. In addition, CBCT clearly demonstrates scutum blunting or destruction, confirming the diagnosis and indicating the extent of lateral wall involvement.

Tegmen tympani integrity. Additionally, erosion of the tegmen raises the risk of dural exposure and cerebrospinal fluid leak during surgery. Therefore, identifying tegmen dehiscence preoperatively allows the surgeon to plan dural repair and to consent the patient appropriately.

Facial nerve canal. Tracing the facial nerve canal through its tympanic and mastoid segments is essential for safe surgical access. CBCT maps the canal course and highlights any dehiscence or displacement by disease. However, the canal wall can be physiologically thin, so apparent dehiscence on imaging should be interpreted cautiously alongside clinical findings.

Lateral semicircular canal. Finally, erosion of the lateral semicircular canal wall by cholesteatoma creates a labyrinthine fistula. This is a finding that significantly alters the surgical approach. CBCT detects bony thinning or frank erosion of the canal wall with high sensitivity due to its sub-millimetre resolution.

Mastoid pneumatisation. In addition, the degree of mastoid pneumatisation influences surgical access and the choice between canal wall up and canal wall down techniques. A sclerotic mastoid, for instance, narrows the surgical corridor and increases the technical difficulty of the procedure.

When to Request CBCT Cholesteatoma Imaging

Not every middle ear condition requires CBCT. However, several specific clinical scenarios make temporal bone CBCT particularly valuable for the referring ENT surgeon.

Preoperative planning for primary cholesteatoma surgery. This is the most common indication. Specifically, the scan maps disease extent, identifies complications, and provides the surgical roadmap described above. The ESR Essentials recommendations confirm CT as first-line preoperative imaging for this purpose.

Congenital cholesteatoma. Similarly, congenital cholesteatoma presents behind an intact tympanic membrane, making clinical assessment of extent especially difficult. In this case, CBCT defines the relationship of the mass to the ossicular chain and surrounding structures before surgery.

Revision surgery assessment. In patients with recurrent symptoms after previous mastoid surgery, CBCT can assess the residual bony anatomy, identify new erosion, and map the modified surgical field. For soft tissue recurrence detection, however, MRI with non-EPI DWI is more appropriate.

Suspected complications. If clinical findings suggest tegmen erosion, facial nerve involvement, or labyrinthine fistula, urgent CBCT provides the bony detail needed for surgical consent and planning.

As with all ionising radiation exposures, referrals for temporal bone CBCT must satisfy the justification requirements under IR(ME)R 2017. The referring clinician must confirm that the imaging will influence clinical management.

CBCT Cholesteatoma Reporting: What the Surgeon Receives

At 3Beam, every temporal bone CBCT includes a structured report from a consultant radiologist. The report systematically addresses each anatomical landmark relevant to cholesteatoma surgery. Specifically, it covers the external auditory canal, tympanic membrane position, ossicular chain integrity, scutum status, tegmen tympani, facial nerve canal, semicircular canals, and mastoid pneumatisation.

This structured approach ensures that no critical finding is overlooked. Furthermore, it provides a standardised reference document for the surgical team. For more information on how structured reporting supports clinical decision-making, see our guide on the importance of structured CBCT radiology reports.

Where clinically indicated, the radiologist may also recommend complementary MRI to evaluate soft tissue extent or to differentiate cholesteatoma from inflammatory tissue. This multimodal approach aligns with current ESR recommendations.

Choosing the Right Field of View for Temporal Bone CBCT

Field of view (FOV) selection directly affects image quality and radiation dose. For cholesteatoma assessment, a small FOV centred on the affected temporal bone is optimal. As a result, this maximises spatial resolution while keeping the radiation dose to a minimum.

A unilateral temporal bone FOV (typically 4 x 4 cm or 5 x 5 cm) provides the highest resolution for middle ear structures. Bilateral imaging is appropriate when the clinical question involves both ears, such as bilateral cholesteatoma or comparison with the contralateral anatomy. For a detailed explanation of FOV considerations, refer to our CBCT field of view selection guide.

Incidental Findings on Temporal Bone CBCT

Temporal bone CBCT may also reveal findings unrelated to the primary indication. For example, these incidental findings can include mastoid air cell opacification, petrous apex lesions, or vascular variants such as a dehiscent jugular bulb. Importantly, each incidental finding requires appropriate documentation and, where necessary, clinical follow-up.

At 3Beam, the reporting radiologist documents all significant incidental findings in the structured report and recommends further investigation when appropriate. For more on this topic, see our guide on CBCT incidental findings: what referring clinicians need to know.

Frequently Asked Questions

Q: Can CBCT cholesteatoma imaging replace MRI?
A: No. CBCT and MRI serve complementary roles. CBCT excels at bony detail for preoperative surgical planning. MRI with non-EPI DWI is superior for soft tissue characterisation and for detecting postoperative residual or recurrent disease. The ESR Essentials recommendations (2025) support CT as first-line preoperative imaging and MRI for postoperative surveillance.

Q: How long does a temporal bone CBCT take?
A: The scan itself takes approximately 20 to 40 seconds. The entire appointment, including positioning and image review, typically takes 15 to 20 minutes. Results and the structured report are usually available within 24 hours.

Q: Is CBCT suitable for children with cholesteatoma?
A: Yes, provided the referral is clinically justified under IR(ME)R 2017. The lower radiation dose of CBCT compared to conventional CT makes it particularly attractive for paediatric patients. However, the longer acquisition time may require additional support to minimise motion artefacts in younger children.

Q: What radiation dose does a temporal bone CBCT deliver?
A: Effective doses for temporal bone CBCT typically range from 0.01 to 0.10 mSv, depending on the scanner and FOV. This is comparable to a few days of natural background radiation and substantially lower than conventional HRCT temporal bone protocols.

Q: Can I refer a patient directly for a temporal bone CBCT?
A: Yes. ENT surgeons, otologists, and other registered healthcare professionals can refer patients directly to 3Beam for temporal bone CBCT. Use our referral form or call 0207 637 8227.

The Bottom Line on CBCT Cholesteatoma Imaging

CBCT cholesteatoma imaging provides ENT surgeons with a high-resolution, low-dose preoperative roadmap of the temporal bone. It maps ossicular chain erosion, identifies tegmen and facial nerve canal dehiscence, and detects labyrinthine fistula with sub-millimetre precision. For primary cholesteatoma surgery, it delivers the bony detail that shapes surgical approach and patient consent. Combined with MRI for soft tissue assessment when needed, it represents a practical and evidence-based imaging pathway for middle ear disease.